A Look At Recursion Pharmaceuticals (RXRX) Valuation After Recent Clinical And Cost Management Updates

Recursion Pharmaceuticals (RXRX) is back in focus after a busy Q1 2026, with fresh clinical data for REC-1245, first patient dosing for REC-4539, and FDA engagement around REC-4881 following promising Phase 2 results.

See our latest analysis for Recursion Pharmaceuticals.

The clinical updates and Q1 results have come with pressure on the stock, with a 30 day share price return of 2.51% contrasting with a 1 year total shareholder return decline of 25.51%, which points to fading longer term momentum despite recent pipeline enthusiasm.

If these AI driven drug programs have caught your attention, it could be a good moment to widen your watchlist using our screener for 35 healthcare AI stocks

With RXRX trading at US$3.27 and some models indicating a possible intrinsic discount of around 64%, yet a 5 year total shareholder return decline of 84%, you have to ask: is this a reset level worth watching, or is the market already weighing all the future growth?

Most Popular Narrative: 66% Overvalued

Compared with the last close at $3.27, the most followed narrative places fair value at $1.97, which points to a steep premium in the current price.

RXRX is a terrible biotech only because the INSIDERS themselves don’t believe in it! All they’re doing is milking the heck out of this doomed stock! Never seen a company where ALL they’re doing insiders are selling! Stock continues to go down every month! CEO said in 2014 that in 10 years there would be 100 new drugs! 12 years later they have ZERO 0️⃣!!! This stock went from over $40 to under $4! The hype is unbelievable! Worst biotech ever!!! Nuff said

Read the complete narrative.

The fair value call in this narrative leans heavily on aggressive margin assumptions, a rich future earnings multiple, and a bold view on revenue momentum. Want to see how those pieces fit together into a single price target?

Result: Fair Value of $1.97 (OVERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, insider selling trends and Recursion Pharmaceuticals' reported net loss of US$559.776 million could still challenge confidence in any optimistic fair value story.

Find out about the key risks to this Recursion Pharmaceuticals narrative.

Another View: DCF Points the Other Way

While the most popular narrative sees RXRX as 66% overvalued at a fair value of $1.97, our DCF model indicates something very different. At $3.27, RXRX is shown as trading 64% below an estimated future cash flow value of $9.09, which raises a different question about what risk is being priced in.

Look into how the SWS DCF model arrives at its fair value.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Recursion Pharmaceuticals for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 51 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

With such mixed signals on value and future potential, it makes sense to move quickly and test the assumptions for yourself using the 2 key rewards and 3 important warning signs.

Looking for more investment ideas?

If RXRX sits on your watchlist, do not stop there. Broaden your opportunity set today and let high quality filters surface ideas you might otherwise miss.

• Spot potential mispricings early by scanning a 51 high quality undervalued stocks that highlights companies with strong fundamentals trading below their implied worth.
• Prioritise resilience by reviewing a 71 resilient stocks with low risk scores focused on businesses with sturdier balance sheets and lower overall risk scores.
• Get ahead of the crowd by searching a screener containing 23 high quality undiscovered gems that surfaces lesser known stocks supported by solid financial profiles.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com